Silk Road Medical Q2 EPS $(0.35) Beats $(0.39) Estimate, Sales $45.30M Beat $43.32M Estimate
Portfolio Pulse from bharat@benzinga.com
Silk Road Medical (NASDAQ:SILK) reported Q2 losses of $(0.35) per share, beating the analyst consensus estimate of $(0.39) by 10.26%. This is a 22.22% increase over losses from the same period last year. The company also reported quarterly sales of $45.30 million, beating the analyst consensus estimate of $43.32 million by 4.57%. This is a 36.55% increase over sales from the same period last year.
August 04, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical's Q2 results beat analyst estimates with losses per share and sales showing increases from the same period last year.
Silk Road Medical's Q2 results exceeded analyst estimates, which is generally a positive signal for investors. The company's losses per share decreased and sales increased compared to the same period last year, indicating improved financial performance. This could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100